Pathologists (ASCO-CAP) guidelines for HER2 testing by fluorescence in situ hybridization (FISH) designated an "equivocal" category (average HER2 copies per tumor cell Ն4-6 with HER2/CEP17 ratio <2.0) to be resolved as negative or positive by assessments with alternative control probes. Approximately 4% to 12% of all invasive breast cancers are characterized as HER2-equivocal based on FISH. OBJECTIVE To evaluate the following hypotheses: (1) genetic loci used as alternative controls are heterozygously deleted in a substantial proportion of breast cancers; (2) use of these loci for assessment of HER2 by FISH leads to false-positive assessments; and (3) these HER2 false-positive breast cancer patients have outcomes that do not differ from clinical outcomes for patients with HER2-negative breast cancer.
A mplification/overexpression of human epidermal growth factor receptor 2 gene (ERBB2, formerly HER2), is associated with shortened disease-free (DFS) and overall survival (OS) in patients whose breast cancers contain this alteration. 1-3 Because targeted therapies using anti-HER2 humanized monoclonal antibodies, [4] [5] [6] [7] small molecule inhibitors of HER2 kinase, [8] [9] [10] and antibody-drug conjugates 11, 12 effectively treat patients with HER2-positive breast cancer, accurate assessment of HER2 status is critically important for treatment selection. Since HER2 protein overexpression is a direct consequence of HER2 amplification, a variety of companion diagnostics are used to identify patients for targeted therapy. During the past decade, the American Society of Clinical Oncology (ASCO) and College of American Pathologists (CAP) have specified criteria for clinical assessment of HER2 amplification status. [13] [14] [15] [16] The most recent full ASCO-CAP guidelines for HER2 testing by in situ hybridization (ISH) changed the evaluation for HER2 amplification requiring formalized assessment of both average HER2 gene number per tumor cell and ratio of average HER2to-internal control chromosome 17 centromere (CEP17) for assessment of HER2 status by fluorescence in situ hybridization (FISH) . 13, 14 This scoring algorithm identifies 5 different breast cancer FISH groupings using HER2 FISH ratio and average HER2 copy number per nucleus. 13, 14, 17, 18 One of these 5 ASCO-CAP FISH groups, designated as ASCO-CAP FISH group 4, 17, 18 is considered "HER2-equivocal" (neither amplified nor not-amplified). 13, 14 According to the guidelines, this ambiguous status may be resolved with alternative controls to replace CEP17 for assessment of HER2 FISH ratios using genes other than CEP17. This approach was widely adopted by both commercial testing laboratories and academic centers. As described, [19] [20] [21] [22] when any of these alternative control probes leads to a HER2-to-control ratio of 2.0 or more, the breast cancer is designated "ISH-positive."
This approach to HER2-equivocal breast cancers contrasts with our experience using alternative controls. 23, 24 Based on early studies of control genes on chromosome 17 2, 3, 25 and preliminary findings from the Breast Cancer International Research Group/Translational Research in Oncology (BCIRG/TRIO) central laboratories, we hypothesized that use of chromosome 17 p-arm controls to establish HER2 gene status of ISHequivocal breast cancers could lead to false-positive classifications in a significant proportion of cases. In this study, we evaluate these hypotheses: (1) genetic loci used for alternative control probes are heterozygously deleted in a substantial proportion of human breast cancers, especially ISH-equivocal cancers; (2) use of these loci for FISH assessment of HER2 status leads to HER2-to-control ratios greater than or equal to 2.0 and, therefore, false-positive assessments of HER2 status; and (3) these HER2 false-positive breast cancers have outcomes that do not differ from behavior established for HER2-negative breast cancers.
Methods
Our study was conducted in 3 parts. The first involved analyses of Molecular Taxonomy of Breast Cancer International Con-sortium (METABRIC) breast cancer data sets to determine relative frequency of deletions in chromosome regions corresponding to probes used as alternative controls on the chromosome 17 p-arm (LIS1, TP53, D17S122, RAI1, and SMS [Smith-Magenis syndrome] region) and q-arm (TOP2A and RARA). The second part involved reassessment of HER2 status in breast cancers from women accrued to BCIRG-005 (ClinicalTrials.gov Identifier NCT00312208) whose cancers had HER2-to-CEP17 FISH ratios of less than 2.0 and an average of 4.0 to 5.99 HER2 genes per tumor cell (ISH-equivocal) or cancers with FISH ratios of less than 2.0 and average HER2 gene copies less than 4.0 per tumor cell (ISH-negative) using alternative control probes to reassess HER2 status, according to the 2013/2014 ASCO-CAP guidelines. 19, 20, 22, 26 Finally, we assessed clinical outcomes in these subgroups.
Analyses of METABRIC Data Set
Publicly available breast cancer genomic copy number data sets, including 1980 patients from the METABRIC 27 cohort (European Genome-phenome Archive, https://ega-archive.org/dacs/ EGAC00001000484) have been profiled on the Affymetrix single-nucleotide polymorphism (SNP) 6.0 array, which includes more than 906 600 SNPs and more than 946 000 copy number probes. Corresponding clinical data were obtained, including tumor estrogen receptor α/progesterone receptor (ER/PR) status, HER2 evaluation by IHC (most samples) or FISH. Linear copy number values for HER2 and alternative probes were compared, as were their copy number states as inferred based on Genomic Identification of Significant Targets in Cancer (GISTIC, version 2.0.23) (https://www.ncbi.nlm.nih.gov/pubmed/21527027/) using default settings. In addition, allele-specific copy number analysis of tumors (ASCAT) 28 total allele counts (corrected for ploidy and purity) were obtained for the METABRIC cohort from Pereira et al. 29 To define the alternative probe regions of interest (LIS1, TP53, D17S122, RAI1, SMS, TOP2A, and RARA), each region was delineated by the position of the gene/genes contained (D17S122 contains CDRT7, PMP22, TEKT3, CDRT4, and TVP23C; SMS contains LLGL1, FLII, TOP3A, and SHMT1; RARA-TOP2A contains RARA and TOP2A). Individual cells were compared by selecting a representative gene from each region (TEKT3 for D17S122, TOP3A for SMS, and TOP2A for RARA-TOP2A).
Patients From the BCIRG-005 Trial
Because the second and third parts of our current study were reassessments of breast cancers designated as ISH-equivocal and ISH-negative by 2013/2014 ASCO-CAP FISH guidelines and because such cases were accrued to the BCIRG-005 trial, our focus was on this trial 30, 31 (Figure 1) (Supplement) . This randomized trial of concurrent TAC or sequential AC-T adjuvant anthracyclinecontaining chemotherapy demonstrated the regimens were equally efficacious but differed in levels of toxic effects. 30, 31 This trial was previously approved by human investigations committees of each institution that accrued patients. Written informed consent was obtained from each patient. The central laboratory obtained institutional review board approval for the characterization of HER2 status of tumor samples from each patient.
We included all patients whose breast cancers were both ISH-equivocal by standard FISH (HER2/CEP17) (183 participants) ( Figure 1 ) and whose breast cancers were successfully hybridized with all alternative controls used in this study to replace CEP17 (TP53, SMS, D17S122, RARA, and TOP2A) (100 participants) ( Figure 1 ) to recalculate the HER2 FISH ratio, as recommended. 13, 14, 19, 21, 22 This portion of our study is based on 100 ISH-equivocal and 100 ISH-negative cases from BCIRG-005 successfully reanalyzed with 5 alternative controls by FISH. For comparison with ISH-equivocal, we selected 100 HER2-not-amplified breast cancers that, according to the guidelines, are ISH-negative (our ASCO-CAP ISH group 5 breast cancers 17, 18 ) beginning with those samples that had an average HER2 gene copy number just less than 4.0 and selected every case in sequential order beginning with 3.99 copies per tumor cell until we had a comparison group of 100 cases that also had successful hybridization with all alternative control probes used in the study (100 participants) ( Figure 1 ).
Laboratory Methods
Tissue sections 6, 17, 32 or tissue microarrays 33 previously analyzed for HER2 gene amplification status were rehybridized and reanalyzed using alternative control chromosome 17 probes (TP53, D17S122, RAI1, SMS, TOP2A, and RARA) by FISH. The primary invasive breast carcinomas of these patients were previously analyzed for HER2 protein expression using immunohistochemical analysis. 17, 18, 32 Among these, 80 ISHequivocal and 100 ISH-negative cases had HER2 immunohistochemical results available for comparison (Supplement). Breast cancers from patients were evaluated in 1 of 2 central laboratories (laboratory) as either human epidermal growth factor receptor 2 gene HER2-not-amplified or HER2-amplified for eligibility to 1 of 3 concurrently conducted clinical trials (BCIRG-005, BCIRG-006, and BCIRG-007). One of the trials, BCIRG-005, required patients whose breast cancers were HER2-not-amplified and the other 2 trials, BCIRG-006 and BCIRG-007, required patients whose breast cancers were HER2-amplified, as determined with fluorescent in situ hybridization (FISH) . Although 10 948 patients were screened in the Breast Cancer International Research Group central laboratories for trial accrual, complete HER2 FISH assay results were available from 10 468 patients for a variety of reasons, including lack of invasive carcinoma in samples submitted, tissue sections that detached from slides during processing, and FISH assay failure owing to lack of probe hybridization. BCIRG-005 randomized patients with HER2-not-amplified breast cancers to sequential (arm 1) or concurrent (arm 2) anthracycline, cyclophosphamide, and docetaxel chemotherapy. BCRIG-006 randomized patients with HER2-amplified breast cancers to standard anthracycline-containing chemotherapy (arm 1, AC-T) alone, AC-T with trastuzumab (arm 2, ACTH) or a nonanthracycline chemotherapy regimen with trastuzumab (arm 3, TCH). The breast cancers from these trials were subsequently pooled according to the ASCO-CAP guidelines for HER2 testing by FISH as recommended into 5 in situ hybridization (ISH) groups, identified in the lower portion of the figure (ASCO-CAP ISH group 5, ASCO-CAP ISH group 4, ASCO-CAP ISH group 3, ASCO-CAP ISH group 2, and ASCO-CAP ISH group 1) and reanalyzed for correlations with HER2 protein expression and clinical outcomes. 17 Since ASCO-CAP ISH group 4 is composed exclusively of HER2-equivocal breast cancers by FISH, the focus of the current investigation, group 4 served as the source of all HER2-equivocal breast cancers (N = 100) characterized in this study by FISH with alternative control probes. As a comparator group, ASCO-CAP ISH group 5, breast cancers were selected for similar analyses by FISH using the same alternative control probes (N = 100). AC-T indicates anthracycline, cyclophosphamide, and docetaxel; ACTH, anthracycline, cyclophosphamide, docetaxel, and trastuzumab; TAC, taxotere, docetaxel, and cyclophosphamide; TCH, docetaxel, carboplatin, and trastuzumab.
HER2 FISH Assays
HER2 FISH assays were performed using the PathVysion assay (Abbott-Molecular, Inc) (Supplement). 17, 18, 32, 34, 35 We characterized HER2-equivocal and HER2-negative breast cancers by FISH with alternative controls (TP53, D17S122, SMS, TOP2A, RARA) according to current full (2013/2014) ASCO-CAP guidelines 13, 14 (Figure 1 ) (eFigure 1 in the Supplement).
HER2 Protein Expression by Immunohistochemistry
The HercepTest (Dako) as well as a laboratory-developed HER2 10H8-IHC assay were used to evaluate HER2 protein expression in the BCIRG-005 trial (Supplement). 17, 18, 32, 35 Statistical Methods 
Results
To evaluate heterozygous deletions of chromosome 17 p-arm and q-arm genomic sites, we used publicly available SNP array data from the METABRIC data set, and confirmed those findings using the same genetic loci by FISH in BCIRG-005 breast cancer specimens.
Evaluation of Heterozygous Deletions in Alternative Chromosome 17 Genomic Regions Based on METABRIC
We identified genomic regions of chromosome 17 reported as alternative control sites for assessment of HER2 FISH ratios. [19] [20] [21] These sites were assessed in METABRIC for copy number gains and losses relative to ERBB2/HER2 gains and losses (Table 1) ( Figure 2 ) (eFigure 1 in the Supplement). Homozygous deletion of any alternative control site was distinctly unusual; however, heterozygous deletions were relatively common, especially on the p-arm of chromosome 17. cohort) (Table 1) ( Figure 2B ) (eFigure 1 in the Supplement). Deletions in LIS1, TP53, D17S122, RAI1, and SMS were observed in 288 (31%), 296 (32%), 281 (30%), 256 (27%), and 246 (26%) of 935 cases, respectively, with concurrent HER2 normal copy numbers (Table 1 ). In contrast, only 17 (1.8%) of 935 METABRIC samples showed loss of RARA and TOP2A (q-arm) with a normal HER2 copy number state (Table 1) .
In METABRIC, 32% of samples demonstrated either a copy number gain or amplification of ERBB2/HER2 with 15% of samples showing high-level gains, considered amplifications. We considered those breast cancers with HER2 copy number "gain" but not "high gain" (amplification) to be most likely representative of ISH-equivocal cancers with increased HER2 (4-6 copies per tumor cell), but not HER2 amplification. Among those with HER2 copy number gain but not amplification, in the p-arm LIS1, TP53, D17S122, RAI1, and SMS regional losses occurred in 201 (62%), 207 (64%), 204 (63%), 183 (56%), and 176 (54%) of 326 cases, respectively (Table 1) ( Figure 2B ) (eFigure 1 in the Supplement). Regional loss on the q-arm (TOP2A and RARA genes) was significantly less frequent (1.84%) (P < .001; OR, 0.01 [95% CI, 0.003-0.025]; Fisher exact test for TETK3 in p-arm and TOP2A in q-arm).
The rate of p-arm alternative control region deletions was even higher among breast cancers with high-level gain or amplification than in the HER2 copy gain cancers (Table 1 ) ( Figure 2B ) (eFigure 1 in the Supplement). Therefore, more than half of the samples with HER2 gain or amplification showed a loss of p-arm regions.
Comparison of HER2 IHC values revealed that IHC 3 + cases in METABRIC exhibited deletions of the alternative control probe loci (eFigure 1B in the Supplement). A similar deletion pattern in the control probes were observed when using the total count of alleles as estimated by ASCAT (correcting by ploidy and purity) (eFigure 1C in the Supplement). Differences were noted be-tween alternative probes located in 17p-arm such that genes located at 17p13-12 (LIS1, TP53, and D17S122) were more frequently deleted than genes at 17p11 (DSS and RAI1)(P < .001; θ = −0.0261; 95% CI, −0.0351 to 0.0171; Mann-Whitney test for TP53 vs DSS in METABRIC). This difference was magnified in amplified samples (P < .001; θ = −0.0533; 95% CI, −0.077 to −0.0299; Mann-Whitney test in METABRIC amplified samples). The negative correlation between HER2 copy-number state (loss, neutral, gain) and alternative probe values was also higher in the 
Chromosome 17 Alternative Control Regions Demonstrate Heterozygous Deletion by FISH
Among 100 ASCO-CAP FISH group 4 (HER2-equivocal) breast cancers, we identified heterozygous deletions ( Table 2 ) (eTable 1 and eFigure 2 in the Supplement)in65fortheSMSlocus,46for D17S122, 43 for TP53,8forTOP2A, none for RARA, and none for HER2 (eTable1intheSupplement). The p-arm alternative control loci had a significantly higher rate of deletions relative to q-arm loci (eTable 1 in the Supplement)(P < .001) with SMS the most frequently lost, followed by D17S122 and TP53.Thefrequency of q-arm heterozygous deletions among HER2-equivocal cancers was low, with only TOP2A reaching 8%. Using the observed average HER2 copy number (varied from 4 to 5.99) per tumor cell divided on a case-by-case basis by the corresponding observed average alternative control copy numbers demonstrated that ratios greater than or equal to 2.0 were observed for 61 cases using SMS, 65 using TP53, and 30 using D17S122 as the denominators in the HER2-to-control ratio calculations. Use of RARA or TOP2A resulted in fewer cases with HER2-to-control ratios greater than2.0(7%and25%)(eTable1intheSupplement). Among 100 ASCO-CAP FISH group 5 (HER2-not-amplified or ISH-negative) breast cancers, we identified heterozygous deletions in 35 cases for D17S122, 30 for SMS, 3 for TOP2A,1for RARA, and none for TP53 (eTable 1 in the Supplement). The parm SMS and D17S122 alternative control loci had significantly higher deletion rates than other loci (eTable 1 in the Supplement)(P < .001). The frequency of p-arm heterozygous deletions among HER2-negative breast cancers was lower than rates observed among HER2-equivocal breast cancers. Nevertheless, use of these alternative controls in ASCO-CAP FISH group 5 breast cancers would lead to significant up-grading of HER2 status to ISH-positive (eTable 1 in the Supplement). Using the observed average HER2 copy number, which varied from 3.99 to 3.25 per tumor cell divided on a case-by-case basis by the correspondingly observed average alternative control copy number, we demonstrated ratios greater than 2.0 for 37 cases using SMS, 12 with RARA, 11 with D17S122, 2 with TP53,and1with TOP2A as the denominators in the HER2-to-control ratio calculations. Similar to HER2-equivocal breast cancers, the use of heterozygously deleted alternative control loci was associated with HER2-to-control ratios equal to or greater than 2.0, consequently, false-positive ratios through status upgrading.
HER2 Protein Expression and Alternative Control Subgroups
The ASCO-CAP FISH group 4 (HER2-equivocal) and ASCO-CAP FISH group 5 (HER2-negative) breast cancers included in this study were associated with low levels of HER2 protein expression by immunohistochemical analysis (eTable 2 in the Supplement). Separation of group 4 and group 5 according to FISH ratios using the various alternative controls did not alter this association for any subgroup by ratio greater than or equal to 2.0, determined with any alternative control probe (eTable 2 in the Supplement), consistent with the interpretation that these alternative control ratios of 2.0 or more do not identify a subgroup of cancers which should be considered for upgrading of HER2 status.
Clinical Outcomes by Alternative Control Subgroups
Within the ISH-equivocal breast cancer patients whose cancers were upgraded to ISH-positive using alternative control probes, there was no subgroup of patients who had a significantly worse disease-free or overall survival compared with either the overall ISH-equivocal or ISH-negative patients or those with a HER2-to-alternative control probe ratio of less than 2.0 ( Figure 3) (eTable 3 and eFigure 3 in the Supplement). Similar observations were made among the patients whose cancers were ISH-negative breast cancer and were upgraded to ISH-positive by the use of alternative control probes.
Discussion
ISH-equivocal, as defined by the 2013/2014 ASCO-CAP guidelines 13, 14 and the recent 2018 update, 36 represent approximately 4% to 12% of all breast cancers, or 7000 to 21 000 patients annually. 17, 18, 20, [37] [38] [39] [40] [41] These cases present patients with breast cancer, oncologists, and pathologists some of their most frequent clinical challenges, because questions remain regarding how HER2 status should be resolved and confusion about HER2-targeted therapies for these patients. Several studies reported the use of alternative controls among patients whose cancers had ISH-equivocal status. [19] [20] [21] [22] 26 In these studies, if any HER2-to-alternative probe ratio was 2.0 or more, the breast cancer was upgraded to ISH-positive. [19] [20] [21] 26 The potential for internal comparator controls to impact assessment of HER2 status was not addressed by previous studies but has concerned us since we began characterizing this alteration. 2, 3, 25 In 2 early investigations of HER2 amplification using the same 345 breast cancers, we used myeloperoxidase gene (MPO) as the internal control (HER2-to-MPO ratio) 3 whereas another group used TP53 (HER-to-TP53 ratio) 42 for assessment of HER2 status. The studies came to different conclusions about both amplification frequency in the cohort (27% vs 33%) and associations with clinical outcomes (significantly associated with DFS and OS 3 vs neither 42 ) using the same shared HER2 gene data by Southern hybridization. 3, 42 The choice of control gene to calculate ratios was the only difference.
The 2013/2014 ASCO-CAP guidelines did not provide data to support use of chromosome 17 alternative probes and the recent 2018 Focused Update did not provide data justifying discontinuation of this approach to resolve the status of ISH-equivocal cancers. Here we used METABRIC data as well as cancers from the BCIRG-005 trial to demonstrate heterozygous deletions among various p-arm and q-arm genomic sites previously used as alternative controls. Our findings indicate heterozygous deletions, particularly at p-arm genomic sites, are relatively common and are not restricted to breast cancers with ISH-equivocal status. In addition, among cancers upgraded by HER2-to-alternative-control ratios of 2.0 or greater there was no significant association with either HER2 protein overexpression or worse clinical outcomes. Our conclusion, that ISH-equivocal breast cancers are HER2-notamplified is also supported by our previous data, 17, 18 which demonstrate that ASCO-CAP FISH group 4 (HER2-equivocal) breast cancers lack HER2 protein overexpression 17, 18 and have patient outcomes 17 that are not significantly different from ASCO-CAP FISH group 5 (HER2-negative or HER2-not-amplified) breast cancer patients. These findings are consistent with the perspective that HER2-equivocal cancers upgraded to HER2-positive are the result of heterozygously deleted alternative control probes. These findings do not mean use of alternative controls for assessment of amplification has no value, only that selection of internal controls should be done carefully with the possibility of heterozygous deletions clearly considered. In our laboratory we have established criteria for the use of such alternative control probes (Table 2) (eFigure2intheSupplement).
Because p-arm genomic sites frequently have heterozygous loss, using a HER2-to-p-arm alternative control ratio in ISHequivocal breast cancers can lead to overestimation of the HER2amplification status. There is a lack of evidence to support the view that HER2 upgraded, ISH-equivocal breast cancers have a clinical disease similar to HER2-amplified breast cancers. We and others 20 show that women with ISH-equivocal cancers upgraded to HER2-positive by p-arm alternative controls do not have significantly worse outcomes than those who are not upgraded. ISH-equivocal cancer patients show outcomes similar to those with ISH-negative disease with no difference in DFS or OS that warrants upgrading to ISH-positive status. We predict lack of responsiveness to HER2-targeted therapies among these patients whose cancers lack HER2-amplification, consistent with previous trials of lapatinib 9 and, more recently, the NSABP-B47 trial of adjuvant trastuzumab in 3270 patients with breast cancers having weakly positive HER2 expression by IHC (1 + ) or moderately positive HER2 expression by IHC (2 + ) but HER2-not-amplified (HER2-negative) by FISH. 43 Therefore, use of HER2-directed therapies in a population falsely classified as HER2-positive is expected to produce inferior clinical and pharmacoeconomic outcomes.
Limitations
The study has some noteworthy limitations. Although a large number of breast cancer cases were available from the METABRIC database for analyses, HER2 gene copy number estimates were based on SNP array data, not HER2 gene copy numbers determined by FISH. In contrast, HER2 gene copy number data were available from the BCIRG-005 trial; however, the number of patients in this trial with long-term clinical follow-up who had breast cancers with HER2 FISH-equivocal (ASCO-CAP FISH group 4) status was limited.
Conclusions
Assessment of HER2 gene status in HER2-equivocal breast cancers is important and clinically relevant. Although approximately half of such HER2-equivocal cases have been upgraded to HER2-positive by FISH using alternative control probes, deletions in these alternative control genomic sites on Among women with HER2-equivocal breast cancers, those who had a SMS alternative control probe ratio Ն2.0 appear to have a slightly better overall survival than those whose breast cancers had a SMS alternative control probe ratio <2.0; however, this difference was not significant. chromosome 17 can lead to false-positive HER2-to-control ratios (greater than or equal to 2.0). We show the genomic sites used to assess these HER2-to-internal control ratios, especially those on the p-arm of chromosome 17, have frequent heterozygous deletions. These deletions, when used for assessment of HER2-equivocal (ASCO-CAP FISH group 4) breast cancers lead to frequent false-positive HER2-to-internal con-trol ratios greater than 2.0. HER2-equivocal breast cancers with these false-positive ratios do not have HER2 protein overexpression and these patients do not have clinical outcomes that differ from either other patients with HER2-equivocal breast cancers not upgraded to positive or from HER2-negative disease. Our findings indicate that HER2 FISH-equivocal breast cancers are HER2-not-amplified. Role of the Funder/Sponsor: The funding organizations had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication. Our earlier studies of HER2 gene amplification as determined by Southern blot analysis 1-3 , indicated that selection of the comparator control gene probes requires considerable caution because, at least some of these control genes may occur at loci frequently deleted in breast cancer, especially TP53 4 . Therefore, use of these deleted sites could lead to false-positive interpretations based on a (HER2 / internal control comparator gene) ratio >2·0 due to reduction of the denominator in the assessment of HER2-to-control gene ratios as opposed to an increase in HER2 gene copy number resulting from bona fide gene amplification. We further predicted that use of alternative control regions for HER2 testing can result in false-positive ISH status due to heterozygous deletions for at least some breast cancers.
eMaterials and Methods.
Patients and Clinical Trials. Between August, 2000 and March, 2004 primary invasive breast carcinomas from 10,468 patients were evaluated for HER2 status by fluorescence in situ hybridization (FISH) in one of two central laboratories to determine eligibility for enrollment in Breast Cancer International Research Group (BCIRG) clinical trials, as described [5] [6] [7] [8] [9] [10] . Because the second part of our current study is a re-assessment of breast cancers designated as "HER2-equivocal" by 2013/2014 ASCO-CAP FISH guidelines and because such cases were systematically excluded from BCIRG-006 and -007 trials, our focus in this study is with the BCIRG-005 trial 6, 7 . This randomized trial of concurrent docetaxel, doxorubicin, and cyclophosphamide (TAC) or sequential (AC-T) adjuvant anthracyclinecontaining chemotherapy in patients with HER2-not-amplified, stage II and III breast cancer demonstrated sequential and combination chemotherapy regimens incorporating three drugs were equally efficacious but differed in toxicity profile 6, 7 . This clinical trial was approved by the human investigations committee of each institution that accrued patients to the BCIRG-005 trial. Written informed consent was obtained from each study participant at the institution accruing the patient. The central laboratory obtained institutional review board approval (IRB number: HS-008070) for the characterization of HER2 status of tumor samples from each patient in this study.
This portion of our study is based on 100 "FISH-equivocal" and 100 "FISH-negative" cases from the BCIRG-005 trial re-analyzed with use of alternative control probes by FISH. Among these, 80 "HER2-equivocal" and 100 "HER2-not-amplified" cases had HER2 immunohistochemistry available for comparison (eTable 2). Laboratory Methods. Fluorescence In Situ Hybridization (FISH) . Patients whose breast cancers were HER2amplified, that is, the tumor cells had a HER2-to-chromosome 17 centromere (CEP17) FISH ratio >2.0 without regard for the average HER2 gene copy number as originally approved by the U.S. Food and Drug Administration (FDA) 11, 12 met an eligibility criterion for BCIRG-006 and BCIRG-007, but were not eligible for BCIRG-005. Whereas those whose breast cancers were composed of tumor cells with a HER2-to-chromosome 17 centromere (CEP17) FISH ratio <2.0 without regard for the average HER2 gene copy number were HER2-not-amplified by FDA-approved criteria and met an eligibility criterion for the BCIRG-005 trial. Only tissue samples from these latter patients were used for the current study of "HER2-equivocal" breast cancers since these had HER2-to-CEP17 ratios <2.0.
As we have reported 8, 13 , the BCIRG-005 trial accrued 183 women whose breast cancers had a HER2-to-CEP17 FISH ratio <2.0 with an average HER2 gene copy number >4.0, but <6.0 per tumor cell nucleus. Of these, 100 were successfully re-evaluated with five different alternative control probes as part of this study. As a comparison group, we also re-evaluated 117 patients whose breast cancers had a HER2-to-CEP17 FISH ratio <2.0 with an average HER2 gene copy number between 3.2 and 3.99 per tumor cell nucleus and were accrued to the BCIRG-005 trial.
This second portion of our report is based on the 200 cases that were successfully analyzed with all alternative control probes by FISH, 100 ASCO-CAP FISH group 4 (HER2-equivocal) and 100 ASCO-CAP FISH group 5 (HER2not-amplified) breast cancers. Among these, 80 "HER2-equivocal" and 100 "HER2-not-amplified" also had HER2 immunohistochemistry available for comparisons. HER2 FISH Assays. HER2 FISH assays were performed using the PathVysion assay (Abbott-Molecular, Inc.), as described 5, 8, 11, 13, 14 . We characterized "HER2-equivocal" and HER2-negative breast cancers by FISH with alternative controls according to current full (2013/2014) ASCO-CAP guidelines 15, 16 . A number of genes located on either the p-arm or q-arm of chromosome 17 (TP53, D17S122, SMS, TOP2A, RARA) were used as alternative controls in place of CEP17 to calculate the HER2-to-control ratio to "resolve" HER2 status of "ISH-equivocal" breast cancers.
We used FISH probes for these chromosome 17 genes to assess HER2 status in ASCO-CAP FISH group 4 "ISHequivocal" breast cancers and in a similar number of ASCO-CAP FISH group 5 (ISH-negative) breast cancers from BCIRG-005. (FISH) Assay Results according to the 2013/2014 ASCO-CAP Guidelines. According to the ASCO-CAP guidelines 15, 16 , in situ hybridization (ISH) assay results are separated into five different groups, based on a combination of average HER2 gene copy number per tumor cell and HER2-to-CEP17 ratios. Three of these groups identify breast cancers that are ISH positive, one ISH equivocal, and one ISH negative. Breast cancers with HER2-to-CEP17 ratios >2.0 are divided in two groups, one with an average HER2 gene copy number of >4.0/tumor cell (our ASCO-CAP FISH group 1) and one with an average HER2 gene copy number of <4.0/tumor cell (our ASCO-CAP FISH group 2). Breast cancers with HER2-to-CEP17 ratios of <2.0 are divided into three additional groups: one with average HER2 gene copy number of >6.0/tumor cell (our ASCO-CAP FISH group 3), which, according to the 2013/2014 ASCO-CAP guidelines for HER2 testing, is also classified as "ISH positive"; another with average HER2 gene copy number of >4.0 but <6.0/tumor cell (our ASCO-CAP FISH group 4), which has been classified as "ISH-equivocal"; and one with breast cancers that contain an average HER2 gene copy number of <4.0/tumor cell (our ASCO-CAP FISH group 5), which is classified as ISH-negative. According to the 2013/2014 ASCO-CAP guidelines breast cancers in groups 1, 2, and 3 are interpreted as ISH-positive, group 4 as ISH-equivocal, and group 5 as ISH-negative. Treatment with HER2-targeted agents is a dichotomous decision. Patients who have ISH-positive breast cancers are eligible for HER2-targeted therapy and those who have ISHnegative breast cancers are not. Therefore, four of the five FISH groups are associated with clinical treatment options, while ASCO-CAP FISH group 4 ("ISH-equivocal") has no clear course of treatment. These patients have cancers that require further resolution into either the "positive" or "negative" categories. Among other remedies, the 2013/2014 ASCO-CAP guidelines have recommended the use of alternative control probes to replace the number of chromosome 17 copies for calculation of a HER2-to-control probe ratio. As described by others [17] [18] [19] [20] , if the ratio is >2.0 using any chromosome 17 alternative control probe, the HER2 status is assessed as "ISH-positive". This latter evaluation presumes that the alternative controls are a better representation of the average chromosome 17 copy number than CEP17, a hypothesis that we are addressing in this investigation.
Interpretation of HER2 Fluorescence In Situ Hybridization
Interpretation of HER2 Fluorescence In Situ Hybridization (FISH) Assay Results using Alternative Control Probes According to Internal Laboratory Specifications. Supportive evidence for heterozygous deletion may be obtained by examining both the distribution of FISH probe signals and the relative number of p-arm gene signals compared with q-arm gene signals assessed as a ratio (average TP53 copy number compared to average TOP2A copy number {ratio}, average SMS copy number compared to average RARA copy number {ratio}, and D17S122 compared to HER2 {ratio}) using a strategy previously established for assessments of 1p (1p36 compared to 1q25) and 19q (19q13 compared to 19p13) deletions in oligodendrogliomas 21, 22 . Although various combinations of p-arm and q-arm genomic site markers have been used, these are the combinations used in this study.
Based on previous observations that the vast majority of breast cancers have either a tetraploid or an aneuploid DNA content in the near tetraploid range 23 , we considered a ratio of <0.75 or >1.25 to presumptively indicate an imbalance in either the p-arm or q-arm genomic locus consistent with heterozygous deletion, as described below. (There were no breast cancers which showed a complete loss of any of these genomic markers by FISH.) The p-arm signals in cases with heterozygous deletions are not only less numerous than the q-arm probe or the HER2 signals, but are also characteristically distributed in a loose pairwise fashion with half to three-quarters of the q-arm signals. The remainder of the q-arm signals are randomly distributed throughout the nucleus without a p-arm partner.
Selection of an appropriate internal control for comparison with HER2 copy number to distinguish gene amplification from copy number aberrations due to chromosome aneusomy or other genomic alterations is important in our laboratory. We have used several different criteria for assessment of gene amplification by FISH. Among breast cancers that lack HER2 amplification, HER2 signals are generally scattered randomly throughout the tumor cell nucleus (Supplemental eFigure 2), not grouped together or "clustered" as expected for an amplicon in a homogeneously stained region of a chromosome (see for example Figure 1B . Such scattered HER2 gene copy number increases are, in our experience with breast cancer cell lines 24 , not associated with increased HER2 protein expression or overexpression.
Since internal comparison genes may be deleted in some cancers, we have devised a strategy to identify these cases by FISH. We routinely process each p-arm locus probe with a q-arm locus probe for pairwise comparison of both the copy number and distribution of signals. Characteristically, in breast cancers lacking p-arm deletions, p-arm and q-arm signals are of similar number and often distributed in a loosely arranged pairwise fashion with these "pairs" randomly distributed throughout the nucleus (Supplemental eFigure 2A-2C). When one probe, usually the p-arm probe, is a quarter to half as frequent as the q-arm probe we consider this to be presumptive evidence for heterozygous deletion of the less frequent locus (Supplemental eFigure 2D-2F).
Finally, for additional support of this interpretation, we confirm that the opposite possibility is not supported by the FISH assay. That is, there is no evidence for "co-amplification" of HER2 with the more frequent, usually qarm probe, by demonstration that HER2 and the more frequent alternative control signals, such as RARA, are NOT colocalized within tumor cell nuclei to the same limited geographic area of nuclei, as would be expected for two genes contained within the same amplicon. In such cancers, we assess the less frequent marker probe as showing heterozygous deletion (Supplemental eFigure 2). These criteria were used to interpret the alternative control probe status reported in Supplemental eTable 1. This strategy is similar to the strategy used to assess 1p and 19q deletions in the evaluation of central nervous system gliomas, particularly oligodendrogliomas, for 1p/19q co-deletion. This assessment is made through a comparison of chromosome 1 p-arm with chromosome 1 q-arm probes (1p36 / 1q25) to assess relative frequency of signals corresponding to each arm 21 . Similarly, a comparison of chromosome 19 q-arm with chromosome 19 p-arm probes (19q13 / 19p13) provides an assessment of relative frequency and, therefore, relative loss or reduction in one arm relative to the other as summarized in Table 2 for the HER2 alternative control probe pairs 21 .
HER2 Protein Expression by Immunohistochemistry. The HercepTest (Dako) as well as a laboratory-developed HER2 10H8-IHC assay were used to evaluate HER2 protein expression 5, 8, 13, 14 in tissue sections of breast cancers from the BCIRG-005 trial. In these "HER2-equivocal" breast cancers, 42 had available results from both IHC assays, 39 had results from only the 10H8-IHC assay, and 19 did not have any IHC available. Among "HER2-negative" breast cancers used in this study, all 100 breast cancers had IHC assay results available, 95 with both assays. When both IHC assays were available the Dako HercepTest was used for the analyses. 
eDiscussion
Since the 1980s we and others have been using various chromosome 17 markers to "normalize" the HER2 gene copy number to determine if HER2 is sufficiently increased to be considered "amplified" 1-3 . A ratio greater than or equal to 2.0, established for Southern hybridization in the 1980s, has proven to be a reasonable "cut-off" for separation of HER2-not-amplified from HER2-amplified breast cancers with the provision, described above, that utilization of heterozygous deleted control genes, such as TP53 as described by Clark and McGuire 4 , or the use of co-amplified genes, such as TOP2A 24 , will lead to false-positive assessments in the former situation and false-negatives in the latter.
Although selection of appropriate chromosome 17 controls is important, the same control may not be useful for assessment of every breast cancer. For example, the use of chromosome 17 centromere (CEP17) for assessment of HER2 by FISH has proven to be a useful control in most cancers. However, in breast cancers where the HER2 amplicon is sufficiently large and extends in a centromeric direction with inclusion of alpha-satellite DNA adjacent to the centromere, the HER2 gene copy number and the CEP17 copy number are both greatly increased (co-amplified), leading to a HER2-to-CEP17 ratio <2.0. In such cases, the use of an alternative control gene, such as RARA, provides a ratio substantially in excess of 2.0. In these HER2 ASCO-CAP FISH group 3A 8, 13 breast cancers an alternative control probe is very useful, as we describe and illustrate elsewhere (see figure 3 and figure 3 legend, in Archives of Pathology and Laboratory Medicine 13 ).
Supplemental Tables. eTable 1. Assessment of Heterozygous Deletions by FISH using Pairwise
Comparisons of Alternative Control Genes and Frequency of resulting HER2 FISH ratios greater than 2.0 using these same Alternative Control Genes: ASCO-CAP Group 4 (HER2-Equivocal) and ASCO-CAP Group 5 (HER2-not-amplified) Breast Cancers. D. TOP2A (orange), TP53 (green) E. SMS (orange), RARA (green) F. HER2(orange), D17S122(green) Breast cancers with similar numbers of p-arm and q-arm markers are interpreted as showing a lack of deletion at those specific genomic sites (A -C). A.) For example, pairwise comparison of TP53 (green) with TOP2A (red) shows similar gene copy numbers with an average TP53 gene copy per tumor cell of 4.05 and an average TOP2A of 3.95 copies per tumor cell for a TP53 / TOP2A ratio of 1.03. Therefore, this pairwise comparison was interpreted as "no deletion" at either site. BCIRG 01502_(Dapi+Orange+Green). B.) Pairwise comparison of SMS (red) with RARA (green) shows similar gene copy number with SMS and RARA both having an average copy number of 1.90 per tumor cell nucleus for a SMS / RARA ratio of 1.00. This pairwise comparison was interpreted as "no deletion" at either site. BCIRG array 1 A8d_(Dapi+Orange+Green) C.) Pairwise comparison of D17S122 (green) with HER2 (red) also shows similar gene copy numbers with D17S122 averages of 2.35 copies per tumor cell and HER2 copy numbers of 2.90 per tumor cell for a HER2 / D17S122 ratio of 1.23 or, as in Table 2 , D17S122 / HER2 ratio of 0.81. This pairwise comparison in the carcinoma cells was interpreted as "no deletion" in either site. BCIRGB IV B5q_(Dapi+Orange+Green) (D.-F.) In contrast, an at least 25% reduction of one of these sites relative to the other site is interpreted as "heterozygous deletion", pending confirmation based on additional considerations of signal groupings (see Table 2 ). D.) Heterozygous deletion of TP53. The average TP53 copy number for this case was 1.50, while the average TOP2A copy number was 2.80 for a TP53 / TOP2A ratio of 0.54, consistent with heterozygous deletion of TP53 relative to TOP2A. BCIRG Array 1 B 5m (Dapi+Orange+Green) E.) Heterozygous deletion of SMS. The average SMS copy number for this case was 1.65, while the average RARA copy number was 3.60 for a SMS / RARA ratio of 0.46, consistent with heterozygous deletion of SMS relative to RARA. BCIRG Array 1 C4h (Dapi+Orange+Green) F.) Heterozygous deletion of D17S122. The average D17S122 copy number for this case was 2.00, while the average HER2 copy number was 3.05 for a D17S122 / HER2 ratio of 0.66, consistent with heterozygous deletion of D17S122 relative to HER2. BCIRG00014 ARRAY 1 A1n_(Dapi+Orange+Green). Original magnification of all images: 1000x.
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